Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 147 citing articles:

SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, et al.
Hypertension (2022) Vol. 79, Iss. 8, pp. 1633-1643
Open Access | Times Cited: 136
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, et al.
Pharmacological Research (2022) Vol. 187, pp. 106597-106597
Open Access | Times Cited: 88
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 80
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2
Sha Chen, Qian Wang, Andriana Christodoulou, et al.
Circulation (2023) Vol. 147, Iss. 3, pp. 276-279
Closed Access | Times Cited: 61
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 60
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Celestino Sardu, Nunzia D’Onofrio, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Keming Huang, Xianling Luo, Bin Liao, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 46
Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry
Jiachen Luo, Xiaoming Qin, Xingxu Zhang, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Simultaneous assessment of stress hyperglycemia ratio and glycemic variability to predict mortality in patients with coronary artery disease: a retrospective cohort study from the MIMIC-IV database
Haoming He, Shuwen Zheng, Yingying Xie, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 19
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 18
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
Raffaele Marfella, Lucia Scisciola, Nunzia D’Onofrio, et al.
Pharmacological Research (2022) Vol. 184, pp. 106448-106448
Open Access | Times Cited: 69
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
Pasquale Mone, Angela Lombardi, Urna Kansakar, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 384, Iss. 1, pp. 116-122
Open Access | Times Cited: 66
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 62
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 53
Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA)
Pasquale Mone, Angela Lombardi, Luigi Salemme, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 450-454
Open Access | Times Cited: 41
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry
Pasquale Paolisso, Luca Bergamaschi, Arturo Cesaro, et al.
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110766-110766
Closed Access | Times Cited: 40
Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: Results from the MIMIC-IV database
Chong Zhang, Hechen Shen, Wei-Ru Liang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 35
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
The Role of Non-Invasive Multimodality Imaging in Chronic Coronary Syndrome: Anatomical and Functional Pathways
Luca Bergamaschi, Anna Giulia Pavon, Francesco Angeli, et al.
Diagnostics (2023) Vol. 13, Iss. 12, pp. 2083-2083
Open Access | Times Cited: 26
Glucose variability: a new risk factor for cardiovascular disease
Martina Belli, Alfonso Bellia, Domenico Sergi, et al.
Acta Diabetologica (2023) Vol. 60, Iss. 10, pp. 1291-1299
Open Access | Times Cited: 26
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102524-102524
Closed Access | Times Cited: 12
Clinical impact of multimodality assessment of myocardial viability
Lisa Canton, Nicole Suma, Sara Amicone, et al.
Echocardiography (2024) Vol. 41, Iss. 7
Closed Access | Times Cited: 9
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Dongmei Wang, J. Y. Liu, Ling Zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Immunomodulation and immunopharmacology in heart failure
George Markousis‐Mavrogenis, Lukas Baumhove, Ali A. Al‐Mubarak, et al.
Nature Reviews Cardiology (2023) Vol. 21, Iss. 2, pp. 119-149
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top